Name: Lenalidomide hemihydrate
Brand: BOC Sciences
Rating: 5 (1 reviews)

Size

Price

Stock

Quantity

$--

In stock

Purity

>98%

Solubility

Soluble in DMSO

Appearance

Solid

Storage

Store at -20°C

Synonyms

Revlimid hemihydrate; CC-5013 hemihydrate

InChI Key

OTJHSDXKMBRCMM-UHFFFAOYSA-N

InChI

InChI=1S/2C13H13N3O3.H2O/c2*14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18;/h2*1-3,10H,4-6,14H2,(H,15,17,18);1H2

Canonical SMILES

C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N.C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N.O

Background Introduction

Lenalidomide hemihydrate is a water-containing form of lenalidomide, one of the most widely studied immunomodulatory drugs (IMiDs) used for its potent and selective modulation of the E3 ligase Cereblon (CRBN). Beyond its established clinical role in treating multiple myeloma and other hematologic malignancies, lenalidomide serves as a foundational E3 ligase ligand in the design and synthesis of PROTACs (Proteolysis Targeting Chimeras) and molecular glue degraders. Its reliable CRBN binding, chemical versatility, and established safety profile make lenalidomide hemihydrate a prime reagent for targeted protein degradation strategies in medicinal chemistry and drug discovery.

Mechanism

As a CRBN-binding ligand, lenalidomide hemihydrate interacts specifically with the substrate receptor CRBN of the CUL4-CRBN E3 ubiquitin ligase complex. In PROTAC or molecular glue configurations, lenalidomide links either covalently or non-covalently with a ligand targeting a protein of interest, effectively recruiting the CRBN ligase to ubiquitinate and flag the target for proteasomal degradation. This process not only suppresses aberrant protein activity but enables targeted degradation of disease-relevant proteins that have been considered undruggable by classical approaches.

Applications

Lenalidomide hemihydrate is widely applied in the synthesis of CRBN-recruiting PROTACs, molecular glues, and other targeted protein degraders. Its use accelerates drug discovery pipelines, aids in target validation, and supports structure-activity relationship (SAR) efforts for degrader optimization. Specific applications include:

• Construction of CRBN-based PROTAC libraries for high-throughput screening
• Design and synthesis of molecular glues for selective degradation of oncogenic or regulatory proteins
• Development of research tools for elucidating protein degradation pathways
• Pharmaceutical and biotech research focusing on novel therapeutic modalities for cancer, inflammation, and autoimmune diseases

• High-purity compound verified by HPLC, NMR, and LC-MS
• Consistent batch-to-batch reproducibility with complete QC documentation
• Supplied with COA, MSDS, and analytical data for traceability
• Reliable global shipping with stability-guaranteed packaging
• Dedicated technical support and optional custom synthesis service
• Demonstrates strong binding affinity to CRBN, VHL, or other E3 ligases
• Enables stable E3 ligase recruitment for targeted protein degradation
• Superior binding affinity for CRBN E3 ligase enhances degradation efficiency in PROTAC applications.
• High purity and hemihydrate form improve solubility and reproducibility in medicinal chemistry research.

1.Lenalidomide, an antineoplastic drug, and its hemihydrate.

Ravikumar K1, Sridhar B. Acta Crystallogr C. 2009 Oct;65(Pt 10):o502-5. doi: 10.1107/S0108270109033642. Epub 2009 Sep 5.

The crystal structures of lenalidomide [systematic name: (RS)-3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione], C13H13N3O3, (I), an antineoplastic drug, and its hemihydrate, C13H13N3O3.0.5H2O, (II), have been determined by single-crystal X-ray diffraction analysis. The overall conformation of the molecule defined by the orientation of the two ring portions, viz. pyridinedione and isoindolinone, is twisted in both structures. The influence of the self-complementary pyridinedione ring is seen in the crystal packing of both structures through its involvement in forming hydrogen-bonded dimers, although alternate dione O atoms are utilized. An extensive series of N-H...O hydrogen bonds link the dimers into two-dimensional supramolecular arrays built up from infinite chains. The water molecule in (II) has a cohesive function, connecting three lenalidomide molecules by hydrogen bonds. The significance of this study lies in the analysis of the interactions in these structures and the aggregations occurring via hydrogen bonds in the hydrated and dehydrated crystalline forms of the title compound.

ConcentrationVolumeMass	1 mg	5 mg	10 mg
1 mM	3.8571 mL	19.2857 mL	38.5713 mL
5 mM	0.7714 mL	3.8571 mL	7.7143 mL
10 mM	0.3857 mL	1.9286 mL	3.8571 mL

Stock concentration: *

Desired final volume: *

Desired concentration: *

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C₁V₁ = C₂V₂